Statement: Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.
Primary_evidence: Outcome Measurement:    Clinical Benefit Rate (CR Plus PR Plus SD)   Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0   CR = disappearance of all target lesions   PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter   SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease   SD is defined as lack of disease progression by 24 weeks.   Time frame: 24 weeks after start of treatment Results 1:    Arm/Group Title: Arm 1 (6 mg Estradiol)   Arm/Group Description: 6 mg of estradiol daily (2 mg tid).   Overall Number of Participants Analyzed: 34   Measure Type: Number   Unit of Measure: participants  Complete response (CR): 0   Partial response (PR): 3   Stable disease (SD): 7 CR+PR+SD: 10 Results 2:    Arm/Group Title: Arm 2 (30 mg Estradiol)   Arm/Group Description: 30 mg of estradiol. (10 mg tid)   Overall Number of Participants Analyzed: 32   Measure Type: Number   Unit of Measure: participants  Complete response (CR): 0   Partial response (PR): 1   Stable disease (SD): 8 CR+PR+SD: 9